Lung cancer screening

LUNGevity Foundation Launches Inhale for Life: Find it Early and Live Public Service and Social Media Campaign During Lung Cancer Awareness Month

Retrieved on: 
Thursday, November 4, 2021
Life, Cancer, Research, Quality of life, Strathcona County, Lung cancer, Prostate, BUT, Survival, Awareness, Human, Health equity, Caregiver, Patient, Public policy, Breast, Education, Medicine, Smoking, Lung cancer screening, Bristol Myers Squibb, CEO, Smoker, CT, Regeneron Pharmaceuticals, VCU Massey Cancer Center, Survivor, Inhalation, AstraZeneca, Boston University, Helpline, Pharmaceutical industry, Medical imaging

WASHINGTON, Nov. 4, 2021 /PRNewswire/ -- LUNGevity , the nation's leading lung cancer-focused nonprofit organization, is kicking off Lung Cancer Awareness Month with the launch of its Inhale for Life: Find it Early and Live public service campaign.

Key Points: 
  • WASHINGTON, Nov. 4, 2021 /PRNewswire/ -- LUNGevity , the nation's leading lung cancer-focused nonprofit organization, is kicking off Lung Cancer Awareness Month with the launch of its Inhale for Life: Find it Early and Live public service campaign.
  • This powerful campaign features the stories of lung cancer survivors whose cancer was diagnosed at stage I, when it is most treatable, greatly increasing their chance of survival.
  • "Detecting lung cancer early, when it is easiest to treat, can save lives," says Andrea Ferris, president and CEO of LUNGevity Foundation.
  • The Inhale for Life: Find it Early and Livevideos showcase six lung cancer survivors who were screened for lung cancer or whose cancer was found during screening for unconnected medical issues.

Berry Oncology Releases Latest Research Results on Early Screening for Multiple Cancers

Retrieved on: 
Wednesday, October 13, 2021
View, HIFI, Liquid biopsy, Technology, Pancreatic cancer, Cancer, Lung, Liver, II, Tissue, Overalls, Lung cancer screening, Mortality, Disease, AUC, CSCO, Multimedia, Patient, Lung cancer, Research, Medical imaging

SHANGHAI, Oct. 13, 2021 /PRNewswire/ -- Berry Oncology, a Chinese oncology genomic testing company, was invited to the inaugural International Biopharma Industry Week in Shanghai (IBIWS) running from October 11-14, where CEOJun Zhoudelivered a much-anticipated keynote speech at the "2021 Future Healthcare Industry Summit" subforum, unveiling the company's latest research results on early screening for multiple cancers.

Key Points: 
  • SHANGHAI, Oct. 13, 2021 /PRNewswire/ -- Berry Oncology, a Chinese oncology genomic testing company, was invited to the inaugural International Biopharma Industry Week in Shanghai (IBIWS) running from October 11-14, where CEOJun Zhoudelivered a much-anticipated keynote speech at the "2021 Future Healthcare Industry Summit" subforum, unveiling the company's latest research results on early screening for multiple cancers.
  • Jun Zhou said, "In this multi-cancer early screening study, Berry Oncology specifically chose lung and gastrointestinal cancers as the breakthrough point as they pose the highest threat in terms of morbidity and mortality in China.
  • From the outset of our product design, we specifically took into account the tumorigenic characteristics of the Chinese population and which cancer most urgently needs early screening solutions."
  • As one of the earliest Chinese companies engaged in the early screening of cancers, Berry Oncology is the first to apply its self-developed HIFI method to the early screening of liver and lung cancers.

Median Technologies Announces Outstanding Performance for its iBiopsy® Lung Cancer Screening CADx1 to Accurately Characterize Malignant vs Benign Lung Nodules Based on a Large-scale Patient Cohort

Retrieved on: 
Monday, September 6, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Medicine, Lung cancer, Medical tests, Clinical medicine, Health, Radiology, Lung nodule, Screening, Cancer screening, Cancer, CT scan, Oncology

Median Technologies (Paris:ALMDT) (ALMDT:PA) announces outstanding performance based on a large-scale lung cancer screening (LCS) patient cohort to characterize malignant vs benign lung nodules based on a deep learning algorithm on low-dose chest computed tomography.

Key Points: 
  • Median Technologies (Paris:ALMDT) (ALMDT:PA) announces outstanding performance based on a large-scale lung cancer screening (LCS) patient cohort to characterize malignant vs benign lung nodules based on a deep learning algorithm on low-dose chest computed tomography.
  • The Median Technologies iBiopsy Lung Cancer Development Plan was launched in February 2021 , as part of the Companys strategic positioning in early-stage disease diagnosis.
  • Major international studies have shown that LDCT lung cancer screening can reduce mortality by 44% (NELSON Trial, 2018).
  • The study was based on a cohort of 1,696 patients from the National Lung Screening Trial cases (NLST) consisting of a total of 15,608 lung nodules.

Delfi Liquid Biopsy Shows Promise for Reducing Lung Cancer Deaths

Retrieved on: 
Friday, August 20, 2021
Nature, Population, Degenerative disease, USPSTF, SCLC, PALO, Death, Cancer, Adoption, Prognosis, Liquid biopsy, DNA, Lung cancer, Disease, COPD, Machine learning, Cough, Nature Communications, Lung cancer screening, Multimedia, LUCAS, Mortality, NSCLC, Delfi, Algorithm, CT, View, MD, Medical imaging, Pharmaceutical industry

Delfi Diagnostics Inc.'s lung cancer screening technology, which uses advanced machine learning algorithms to analyze genome-wide cell-free DNA fragmentation profiles, was able to detect approximately 90% of cancer cases in a group of nearly 800 individuals who underwent lung cancer screening with a low-dose CT (LDCT) scan.

Key Points: 
  • Delfi Diagnostics Inc.'s lung cancer screening technology, which uses advanced machine learning algorithms to analyze genome-wide cell-free DNA fragmentation profiles, was able to detect approximately 90% of cancer cases in a group of nearly 800 individuals who underwent lung cancer screening with a low-dose CT (LDCT) scan.
  • Lung cancer is the leading cause of cancer deaths, with the vast majority of lung cancers detected at late stages when prognosis is poor.
  • "These results suggest that the Delfi lung cancer screening technology could help reduce lung cancer deaths by offering a convenient, high-performing test to people who are USPSTF eligible," said Delfi CMO Peter B. Bach, MD.
  • Delfi is developing a new class of liquid biopsy for early detection based on altered genome-wide fragmentation profiles, also known as "fragmentomes," a result of disordered packaging of DNA in cancer cells.

American Lung Association on World Lung Cancer Day Announces New Patient Resources and Trends Brief

Retrieved on: 
Thursday, July 29, 2021
Health effects of tobacco, Lung cancer, Cancer, Health, Medicine, War on Cancer, Lung cancer screening

CHICAGO, July 29, 2021 /PRNewswire/ --In recognition of World Lung Cancer Day, the American Lung Association announced new patient resources and a lung cancer trends brief to further advance support for lung cancer patients and caregivers.

Key Points: 
  • CHICAGO, July 29, 2021 /PRNewswire/ --In recognition of World Lung Cancer Day, the American Lung Association announced new patient resources and a lung cancer trends brief to further advance support for lung cancer patients and caregivers.
  • Lung Cancer Trends Brief: New this year, the Lung Association released this data on lung cancer mortality, incidence, prevalence and other key measures of the burden of this disease.
  • "World Lung Cancer Day presents a meaningful opportunity to highlight our new and existing lung cancer resources that offer support for those impacted by this devastating disease, while building additional awareness across the country," said American Lung Association National President and CEO Harold P. Wimmer.
  • The American Lung Association created LUNG FORCE, a national movement to defeat lung cancer, the leading cancer killer of women and men.

AdventHealth Ocala Using Innovative Technology for Lung Cancer Diagnosis

Retrieved on: 
Thursday, July 15, 2021
Lung cancer, AdventHealth, AdventHealth Ocala, Lung cancer screening, Cancer screening, Ocala, Florida, Cancer, Florida, Health

OCALA, Fla., July 15, 2021 /PRNewswire-PRWeb/ -- AdventHealth Ocala is the 14th hospital in Florida and the first in Marion County to implement the innovative MONARCH platform to fight lung cancer.

Key Points: 
  • OCALA, Fla., July 15, 2021 /PRNewswire-PRWeb/ -- AdventHealth Ocala is the 14th hospital in Florida and the first in Marion County to implement the innovative MONARCH platform to fight lung cancer.
  • "We are excited to add this option technology to our facility as we continue to build on our Lung Cancer Screening Center of Excellence designation and offer a more hopeful future for our patients with lung cancer," said Dr. Michael Torres, Chief Medical Officer, AdventHealth Ocala.
  • "We are focused on earlier detection and diagnosis of lung cancer to increase the chances of survival in our community," said Dr. Raj G. Karunakara, Medical Director of the Lung Health program at AdventHealth Ocala.
  • AdventHealth Ocala is a designated Screening Center of Excellence for Lung Care by the GO2 Foundation for Lung Cancer.

Thynk Health Welcomes Kim Parham as Vice President of Strategic Partnerships and Clinical Liaison

Retrieved on: 
Monday, July 12, 2021
Medicine, Lung cancer, Cancer screening, Health effects of tobacco, Medical terminology, Health, Lung cancer screening, Cancer, Screening

LEXINGTON, Ky., July 12, 2021 /PRNewswire/ -- Thynk Health, the Complete Lung Cancer Screening Solution, announced and welcomed Kim Parham as VP of Strategic Partnerships and Clinical Liaison as the company enters into a new wave of growth and business development.

Key Points: 
  • LEXINGTON, Ky., July 12, 2021 /PRNewswire/ -- Thynk Health, the Complete Lung Cancer Screening Solution, announced and welcomed Kim Parham as VP of Strategic Partnerships and Clinical Liaison as the company enters into a new wave of growth and business development.
  • She is excited to be joining the Thynk Health team offering technology solutions that improve patient outcomes while helping increase facility revenue.
  • Thynk Health is on a mission to save lives lost to lung cancer by disrupting outdated, burdensome lung cancer screening processes.
  • Thynk Health's platform optimizes data-driven workflows and provides operational and clinical analytics for cancer screening programs and incidental findings management.

Dr. Peter Bach Joins Delfi Diagnostics as Chief Medical Officer

Retrieved on: 
Wednesday, June 23, 2021
Medicine, Clinical medicine, Cancer screening, Lung cancer, Medical tests, Lung cancer screening, Liquid biopsy, Screening, Cancer, Biopsy, Molecular diagnostics

BALTIMORE, June 23, 2021 /PRNewswire/ --Delfi Diagnostics, a developer of next-generation high performance, affordable liquid biopsy tests for early cancer detection, announced today that Peter B. Bach, MD, a lung cancer screening pioneer and health economics expert, has joined as Chief Medical Officer.

Key Points: 
  • BALTIMORE, June 23, 2021 /PRNewswire/ --Delfi Diagnostics, a developer of next-generation high performance, affordable liquid biopsy tests for early cancer detection, announced today that Peter B. Bach, MD, a lung cancer screening pioneer and health economics expert, has joined as Chief Medical Officer.
  • Dr. Bach created the first lung cancer risk prediction model, and such models are now widely used to predict the likelihood of heavy smokers developing lung cancer.
  • He led numerous lung cancer screening guideline panels, and as a private citizen initiated the request to Medicare that resulted in nationwide coverage of lung cancer screening.
  • Founded in 2019, Delfi Diagnostics is committed to developing high-performing, affordable blood tests for early detection of cancer across multiple tumor types.

Owensboro Health Partners with Eon to Fight Lung Cancer

Retrieved on: 
Tuesday, June 22, 2021
Medicine, Lung cancer, Cancer screening, Health effects of tobacco, Lung cancer screening, Health, Owensboro Health, Screening, Clinical medicine, Cancer, Owensboro, Kentucky

DENVER, June 22, 2021 /PRNewswire/ -- Eon , a Denver-based healthtech leader, announces today that Owensboro Health has implemented Eon EPM for lung cancer screening and in cidental finding patient triage and tracking to increase the reach and effectiveness of its lung cancer program.

Key Points: 
  • DENVER, June 22, 2021 /PRNewswire/ -- Eon , a Denver-based healthtech leader, announces today that Owensboro Health has implemented Eon EPM for lung cancer screening and in cidental finding patient triage and tracking to increase the reach and effectiveness of its lung cancer program.
  • "At Owensboro Health, our mission is to heal the sick and to improve the health of the communities we serve.
  • Lung cancer screening is a vital part of that mission, and the addition of Eon EPM is making our program even stronger."
  • Christine Spraker, co-CEO of Eon, elaborates on the partnership with Owensboro Health, saying, "Kentucky is notorious for high lung cancer mortality, but comprehensive programs are seeing significant improvements.

2021 ASCO - AnchorDx Unveils Robust Validation Result of Multi-cancer Screening Technology AURORA

Retrieved on: 
Monday, June 21, 2021
Medicine, Cancer screening, Cancer, Clinical medicine, Medical terminology, Lung cancer screening, Screening, Breast cancer, Oncology, Prostate cancer screening

GUANGZHOU,China, June 21, 2021 /PRNewswire/ -- At this year's American Society of Clinical Oncology (ASCO) Annual Meeting 2021 (June 4-8), AnchorDx, a world-leading developer of cancer screening and early detection solutions, unveiled further validation results on the generalization performance of its multi-cancer screening technology Aurora in breast and gastric cancer screening models.

Key Points: 
  • GUANGZHOU,China, June 21, 2021 /PRNewswire/ -- At this year's American Society of Clinical Oncology (ASCO) Annual Meeting 2021 (June 4-8), AnchorDx, a world-leading developer of cancer screening and early detection solutions, unveiled further validation results on the generalization performance of its multi-cancer screening technology Aurora in breast and gastric cancer screening models.
  • AnchorDx is presently accelerating the prospective studies of Aurora multi-cancer screening and a comprehensive assessment of Aurora in terms of testing performance, testing accessibility and convenience with plans to launch multi-cancer screening LDT service in the third quarter of this year.
  • Founded in 2015, AnchorDx is a world-leading developer of cancer screening and early detection solutions based on methylation NGS technology.
  • In addition, AnchorDx has a proprietary big data and artificial intelligence platform designed for early lung cancer screening, diagnosis, and treatment.